Skip to main content
05_Bernardo_Franklin
© Photo: Bruna Guerra Photography

News categories: Honors & Funding

ERC Proof of Concept Grants for UNBIAS

European Research Council is supporting the journey from basic research to application

Prof. Bernardo Franklin from the Institute of Innate Immunity at the University Hospital Bonn has been awarded a Proof of Concept Grant by the European Research Council (ERC) as part of a program designed to help researchers translate their ideas from previous ERC projects into commercial applications. The project is awarded with a funding of €150,000, provided over a period of around one year.

ImmunoSensation2 member Prof. Dr. Bernardo S. Franklin studies hematopoietic stem cells (HSCs), which develop into different blood cells through processes of cell division and differentiation. “Bouts of inflammation that a person experiences as they get older will damage these stem cells,“ Bernardo S. Franklin says. “Processes like this cause hyperactivation of the innate immune system in the elderly.” This phenomenon, known as “inflammaging,” increases the risk of conditions including cardiovascular disease, diabetes and cancer, he adds.

“Wiping” the immune system’s harmful memories of inflammation


The project that has now secured ERC funding, which is entitled “Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation” (UNBIAS), aims to return HSCs to their original state in order to “wipe” the immune system’s harmful memories of inflammation. The researchers are using customized “mini-antibodies” known as nanobodies to achieve this. These antibodies, which are very small in relative terms, are taken from the blood of alpacas and can break up the places where inflammation develops.

Back in 2017, Franklin received a much-sought-after Starting Grant from the ERC worth some €1.5 million in funding. The Proof of Concept Grant will now build on this work already done. “Our aim is to validate the use of nanobodies to combat inflammaging and license this technology or its applications for industrial partners,” Franklin says. He believes that the project has the potential to alleviate the effects of inflammation and thus potentially save countless lives and the economic cost of illness.

Contact

Prof. Dr. Bernardo S. Franklin

Institute for Innate Immunity

University Hospital Bonn

Phone +49 228 28751981

Email: franklin@uni-bonn.de

Related news

Prof. Dr. Bernando S. Franklin

News categories: Honors & Funding

Funding of €6.9 Million for Sepsis Research

Every year some 75,000 people die from bacterial blood poisoning, or sepsis, in Germany alone. Survivors of sepsis often struggle with secondary and concomitant conditions due to the resulting impairment of the immune system, the so called “Immunesuppression”. The International Center for Clinical Research (ICRC) at St. Anne's University Hospital (FNUSA) Brno (Czech Republic) has founded the research consortium “BEATSep”. HORIZON EUROPA is funding it with around 6,9 million euros over the next five years.
View entry
Nicole_Glodde_News_09.2023

News categories: Honors & Funding

Unraveling the role of NLRC5 in melanoma progression

Immunotherapies offer new perspectives in the treatment of cancer. Unfortunately, tumor immune-escape mechanisms limit their effectiveness on a long turn. The intracellular receptor NLRC5 impacts the regulation of tumor recognition by the immune system in melanoma and other entities and is hence at the core of a new research project by ImmunoSensation² member Dr. Nicole Glodde from the Institute of Experimental Oncology at the University Hospital Bonn. The project is funded by the German Hiege Foundation, providing 30.000 € over the period of one year.
View entry
Prof. Gabor Petzold

News categories: Honors & Funding

Research on the Brain’s Detox System

Prof. Gabor Petzold, a neuroscientist at DZNE and University Hospital Bonn (UKB), is part of a new US and European network of excellence funded by the Leducq Foundation with a total of US$ 8 million. Of this, about US$ 400,000 go to Bonn. The consortium will investigate the role of so-called brain clearance in cerebral amyloid angiopathy (CAA). This condition is a major cause of hemorrhagic stroke, as well as an important factor in certain forms of dementia. As the population ages, CAA is on the rise.
View entry

Back to the news overview